Vontobel Holding Ltd. Acquires 30,000 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Vontobel Holding Ltd. boosted its stake in Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 230.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,000 shares of the biotechnology company’s stock after acquiring an additional 30,000 shares during the period. Vontobel Holding Ltd.’s holdings in Adaptimmune Therapeutics were worth $41,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Long Focus Capital Management LLC lifted its position in shares of Adaptimmune Therapeutics by 15.6% in the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock worth $12,037,000 after purchasing an additional 1,662,184 shares during the period. Renaissance Technologies LLC increased its position in shares of Adaptimmune Therapeutics by 28.3% during the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after buying an additional 394,566 shares during the period. Boulder Hill Capital Management LP bought a new position in Adaptimmune Therapeutics in the first quarter worth about $143,000. Finally, JTC Employer Solutions Trustee Ltd purchased a new stake in Adaptimmune Therapeutics in the first quarter worth about $41,000. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Trading Down 3.1 %

Shares of NASDAQ ADAP opened at $0.78 on Thursday. The stock has a market cap of $193.73 million, a P/E ratio of -1.09 and a beta of 2.20. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.09 and a quick ratio of 3.09. Adaptimmune Therapeutics plc has a 1 year low of $0.42 and a 1 year high of $2.05. The firm has a 50-day moving average of $1.03 and a 200 day moving average of $1.08.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Monday, August 12th. The biotechnology company reported $0.27 earnings per share for the quarter. The company had revenue of $128.23 million for the quarter, compared to the consensus estimate of $58.00 million. Adaptimmune Therapeutics had a negative return on equity of 116.80% and a negative net margin of 51.25%. As a group, sell-side analysts expect that Adaptimmune Therapeutics plc will post -0.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ADAP. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Adaptimmune Therapeutics in a report on Tuesday, August 13th. StockNews.com raised Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 13th.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.